Jeffrey Eisele - 25 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Exec VP, Program Team Lead
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
25 Apr 2022
Transactions value $
-$4,600
Form type
4
Filing time
23 Dec 2022, 15:15:35
Previous filing
01 Feb 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -1.25K -3.79% $0.00 31.7K 25 Apr 2022 Direct F1
transaction APLS Common Stock Tax liability -$4.6K -89 -0.28% $51.68 31.7K 22 Dec 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This represents shares used to cover tax withholding on a Restricted Stock Unit release.